Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP
Corbus Pharmaceuticals — Investor Presentation (August 2017)
40 slides from Corbus Pharmaceuticals's investor presentation, Aug 22, 2017
Slide 1: Developing Breakthrough Therapies for Rare Inflammatory and Fibrotic Diseases
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains certain forward-looking statements, including those relating to the Company’s product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, bus
Slide 3: Overview
x Overview First-in-class Anabasum | oralsynthetic endocannabinoid TInt Launching Focus on rare, chronic, serious ih inflammatory and fibrotic diseases t Intellectual Property =>
Slide 4: Leadership Team
Leadership Team Management Yuval Cohen, PhD Chief Executive Officer, Director Co-founder and former President of Celsus Therapeutics (CLTX). Expertise in developing antiinflammatory drugs including for CF Sean Moran, CPA, MBA Chief Financial Officer Former CFO: InVivo (NVIV), Celsion (CLSN), Transpo
Slide 5: Anabasum Pipeline: Multiple Opportunities in Rare Autoimmune / Inflammatory / Fibrotic Diseases
~ Anabasum Pipeline: Multiple Opportunities in Rare Autoimmune / Inflammatory / Fibrotic Diseases Patient Phase of Orphan FastTrack | Open-Label | Nondilutive resents Population | Development | Designation Status Extension | Funding Plan to commence Systemic Sclerosis 90,000 Launch (SSe) (US+EU) Pha
Slide 6: Normal Inflammatory Process vs. Chronic Inflammation
Normal Inflammatory Process vs. Chronic Inflammation Normal Inflammation Process Inflammatory / Fibrotic Disease Chronic Inflammation / Fibrosis 2 2 2 2 2 2 =| Activation Resolution iE | Activation c =f 2 2 oS oS £ € £ £ a a = = Time Time Immune System Returns to Homeostasis Immune System is Unable
Slide 7: Anabasum Promotes Resolution of Inflammation and Fibrotic Responses
y Anabasum Promotes Resolution of Inflammation and Fibrotic Responses Resolution of Chronic Inflammation and Fibrosis Anabasum: Triggers Resolution of Innate Immune Responses ¥ Pro-inflammatory lipids a N ¥ Vasodilation | edema i) AS ¥ Chemokines ing lipid medi g 1 a ¥ Pro-resolving lipid mediators
Slide 8: Endocannabinoids Play a Unique Role in Inflammation and Fibrosis
x Endocannabinoids Play a Unique Role in Inflammation and Fibrosis MOA of CB2 agonism: triggering of resolution of innate immune responses’ Resolution of Inflammation and Fibrosis Endocannabinoid System CORBUS) 8 _s:Shinohara 2012
Slide 9: Unique Characteristics of Anabasum Make It an Attractive Candidate
x Unique Characteristics of Anabasum Make It an Attractive Candidate for Rare + Chronic Inflammatory / Fibrotic Diseases High ) Low ») Targeting ea mg — sees Inflammation Without *CB2 Binding Affinity °CB1 Binding Affinity Immunosuppression (Pro-resolution receptors in (Analgesic receptors in the mm
Slide 10: Systemic Sclerosis
- Commencing Phase 3 study in Q4 2017 - Potential approval in 2020
Slide 11: Systemic Sclerosis
afi Systemic Sclerosis Chronic systemic autoimmune disease causing fibrosis of skin and internal organs eG +EU henna (0) eeceee gun REPT 40-60 Years Average age of patients Lung Fibrosis i Common cause of death - ER 40%-60% mortality in 10 years Key Takeaways Life-threatening, rare disease (:) No SS
Slide 12: Design of Phase 2 Study
x Design of Phase 2 Study Positive Results of Double-blinded, Placebo-controlled L Portion of Trial Reported in November 2016 Double-blind clinical sites randomized, placebo-controlled 9 aie the U.S. 43 Adu Its RERERRERER anabasum:placebo att 16 week study — 12 week active dosing Ys wy GZ «: Ga S Ga
Slide 13: Safety and Tolerability Summary
x Safety and Tolerability Summary « Anabasum was well tolerated « No serious or severe anabasum-related TEAEs noted « Most common adverse events were mild/moderate: - Dizziness (22% in anabasum-treated subjects vs. 13% in placebo-treated subjects) - Fatigue (19% in anabasum-treated subjects vs. 7% i
Slide 14: mRSS: Skin Thickening Improved
Change in mRSS, LS means +SE mRSS Change from Baseline —®- Anabasum —e—Placebo =< x mRSS: Skin Thickening Improved Primary Endpoint in Upcoming Phase 3 Study * mRSS improved at week 16 from baseline -4.7 + 1.1 (SE) for anabasum subjects vs. -2.0 + 1.5 for placebo subjects CORBUS)y
Slide 15: Improved Patient Reported Skin Symptoms
Improved Patient Reported Skin Symptoms SSc Skin Symptoms Questionnaire* 5-D Itch Questionnaire” = e S & u Sitch score, change from baseline P?=0.044 P=0.004 P? = 0.032 ° 4 2 ° 4 2 ‘SScSkin Questionnaire score, change from baseline —®— Anabasum —®—Placebo: Reduction = improvement * Greater improveme
Slide 16: Improvements in ACR-CRISS Scores
Improvements in ACR-CRISS Scores Median ACR CRISS Score P1 = 0.044 lm Anabasum (n=26) ™@ Placebo (n=15) ES o Ps 9 9 a yn a) “ oO * Composite score of change from baseline in mRSS, HAQ-DI, FVC % predicted, and physician and patient global assessments * mRSS represents largest weighted factor in ACR-C
Slide 17: Additional Efficacy Outcomes Favor Anabasum
- Additional Efficacy Outcomes Favor Anabasum HAQ-DI, Change from Baseline FVC % Predicted, Change from Baseline MDGA, Change from Baseline 25 2 1s 1 os ° os a 15 PIGA, Change from Baseline oa _ Change in HAG.0I, 1S means 2SE Cchange in mEVC, Ls means 4sE ‘Change in MOGA, LS means SE Change in PGA,
Slide 18: On Target Effect: Anabasum Reduces Inflammation in Skin
- On Target Effect: Anabasum Reduces Inflammation in Skin (Histology Analysis) Change in inflammation after only 12 weeks of treatment Placebo Anabasum 90/0 P = 0.008 Fisher's exact test A8% two-sided 48%, AmRSS = -1.2 AmRSS = -5.1 Improved Unchanged #Worsened 18 19 Ti...
Slide 19: On Target Effect: Anabasum Reduces Fibrosis in Skin
Analysis) x On Target Effect: Anabasum Reduces Fibrosis in Skin (Histology Change in fibrosis after only 12 weeks of treatment Placebo Anabasum 15% P=0.049 . A3% Fisher's exact test 39% two-sided 48% AmRSS = -1.8 AmRSS = -4.0 Improved Unchanged #Worsened 19 tg...
Slide 20: Planned Design of Upcoming Phase 3 Study
x Planned Design of Upcoming Phase 3 Study Phase 3 Study Scheduled to Commence Q4 2017 Double-blind Multinational ~300 Subjects randomized, placebo-controlled ee 52 week study “Y Ki Ji 4 x 2 Primary Endpoint: Secondary Endpoints: * Change from baseline in mRSS * Change from baseline in HAQ-DI * ACR
Slide 21: Cystic Fibrosis
- Exper Set commence tudy in Q4 2017
Slide 22: Cystic Fibrosis
22 Cystic Fibrosis CF is a life-threatening, genetic disease that primarily affects the lungs and digestive system. CF is characterized by chronic lung inflammation that leads to lung damage and fibrosis. 30,000 rie Patients in the U.S. 75,000 eoceecec coe Patients worldwide RREET Tt" 40 YEARS Avera
Slide 23: Inflammation: A Key Driver of CF Morbidity and Life-Span
x Inflammation: A Key Driver of CF Morbidity and Life-Span | Potential to be First Approved Therapy Targeting Inflammation and Fibrosis in CF Underlying Additional sf : 2 Ee Damage > Fibrosis ) Inflammation Inflammation y y / — —_ = = —— 4 ” 4 Birth / early ehildnood Pulmonary Exacerbations CORBUSY
Slide 24: Pulmonary Exacerbations
Ee) Increased dangerous manifestation of lung disease in CF inflammation precedes PEx Irreversable lung function loss, including loss of FEV1 Wp MW Increased shortness WONDM of breath, cough, sputum production and reduced FEV1 $3? Patients with CF SS a 6a 6 can have Treatment multiple cost can reach
Slide 25: Design of Completed Phase 2 Study
Design of Completed Phase 2 Study Po: Double-blind 21 cinisteeees 5 Adults randomized, placebo-controlled e Data Announced March 2017 16 week study — 12 week active dosing ttitt 5 :2 overall ratio of anabasum:placebo Secondary Objectives: » FEV1 % predicted, lung clearance index and CFQ-R * Blood an
Slide 26: Safety and Tolerability Summary
x Safety and Tolerability Summary » Anabasum was well tolerated » No serious or severe anabasum-related TEAEs noted « Most common anabasum-related mild adverse event: - Dry mouth (mild, 13% vs 0% in placebo) ° FEV-1 remained stable throughout the study across all cohorts
Slide 27: Pulmonary Exacerbation Requiring Treatment with IV Antibiotics
Pulmonary Exacerbation Requiring Treatment with IV Antibiotics Weeks 1-4 03 03 02 02 o1 01 il Placebo Events per subject per 12 weeks Rate of Pulmonary Exacerbations Requiring IV ‘Antibiotics: 03 Placebo 20mg 20 mg bid Weeks 5-12 « Pulmonary exacerbations (PEx) captured as an event of special intere
Slide 28: Pulmonary Exacerbations Treated with Any New Antibiotic
Pulmonary Exacerbations Treated with Any New Antibiotic Rate of Pulmonary Exacerbations Requiring New Antibiotics \ ° A broader look at acute pulmonary exacerbations as defined by treatment with Weeks 1-4 Weeks 5-12 any new antibiotics for respiratory system 08 08 symptoms a or » Reduction from plac
Slide 29: Consistent Reduction in Key Inflammatory Biomarkers (Sputum)
' Consistent Reduction in Key Inflammatory Biomarkers (Sputum) Reduction with anabasum 20 mg BID compared to placebo (Log,9) Neutrophils, cells/m| p= 0.068 —_______f Eosinophils, cells/ml p= 0.089 Lymphocytes, cells/ml Macrophages, cells/ml Neutrophil elastase, mcg/ml IL-8, pg/mL IgG, mg/dl 25 a2 “1
Slide 30: Dermatomyositis & Systemic Lupus Erythematosus
Dermatomyositis & Systemic Lupus Erythematosus: - Dermatomyositis - Ongoing Phase 2 study - topline results expected Q4 2017 - Ongoing open-label extension - NIH funded - Systemic Lupus Erythematosus - Launching Phase 2 study Q4 2017 - NIH funded CORBUS ¥ PHARMACEUTICALS 30
Slide 31: Dermatomyositis
31 Dermatomyositis Chronic systemic autoimmune disease characterized by inflammation of skin and muscles ee U.S. + EU feeeT SKIN & MUSCLE Involvement can cause significant morbidity and mortality from interstitial lung disease NO FDA Approved therapies for overall disease activity Key Takeaways be D
Slide 32: Dermatomyositis Phase 2 Clinical Study
Dermatomyositis Phase 2 Clinical Study Topline Results Expected Q4 2017 Double-blind 1 Site _ University of Pennsylvania 22 Adults randomized, placebo-controlled __ Perlman School of Medicine 16 week study — 12 week active dosing Vv >» sy Pod 20mg QD Wig Be 20mg BID Weg y Oe - Gy & with refractory s
Slide 33: Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
y Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) CDASI was developed to measure multiple inflammatory elements in the skin’ Measurement Location Disease Severity SCALP PERIORBITAL ALAR AREA. REST OF THE FACE POSTERIOR NECK. \V-AREA NECK (FRONTAL) ine i: a ‘ABDOMEN REST OF BACK, DO
Slide 34: Systemic Lupus Erythematosus
Systemic Lupus Key Takeaways Erythematosus Chronic systemic autoimmune disease ae : characterized by arthritis, skin rashes, kidney Treated with immunosuppressive disease, and involvement of the nervous system therapies and other organs £00,000, = 600.000 — atients in the U.S. + ee © © eo ultil-cent
Slide 35: Systemic Lupus Erythematosus Phase 2 Clinical Study
Systemic Lupus Erythematosus Phase 2 Clinical Study Commence Patient Enrollment Expected Q4 2017 Double-blind 15 oe 100 Adults with sie randomized, placebo-controlled 2 uc 16 week study — 12 week active dosing iis rH & ” Ps a > =-ep- mates Secondary Endpoints: * Efficacy in overall disease activity,
Slide 36: Scientific Advisory and Principal Investigators
3 Scientific Advisory and Principal Investigators Scientific Advisors Principal Investigators ‘THE UNIVERSITY of NORTH CAROLINA at CHAPEL MILL. Michael Knowles, MD, PhD mu HARVARD MEDICAL SCHOOL Charles Serhan, PhD Robert Spiera, MD US PI -SSc 7a HOSPITAL FOR MS SPECIAL SURGERY Christopher Denton, P
Slide 37: Clinical Development Milestones
Clinical Development Milestones O4 2017 SSc SLE Launch Phase 3 study Expected launch of Topline data from Phi 2b stud! eee. Phase 2 study Start Phase 2 study Interim data from 2 open-label study Phase 2 data to be presented at NACFC-17 Extend duration of open-label study CORBUSY 37.
Slide 38: Financial Profile: CRBP (NASDAQ)
x Financial Profile: CRBP (NASDAQ) Strong Financial Position and Liquid Trading Market for CRBP $78MM $301 MM a2 mm Raised to-date 562K $43MM 50d average + Market cap* outstanding $20MM daily volume* Cash balance** (57.8MM fully diluted) iaorecinaes ung ot N.LH. and CF Foundation sons 90 esngpeesnpe
Slide 39: Summary
x Summary First-in-class drug targeting inflammation and fibrosis Solid execution with multiple milestones in Q4 2017 @ Positive clinical data in &2 rare diseases with no currently approved therapies 39
Slide 40: Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc. 617.963.0100 info@corbuspharma.com www.corbuspharma.com 100 River Ridge Drive Norwood, MA 02062 40
Corbus Pharmaceuticals Holdings — Investor Presentation (August 2017) on 6ix